Better Care for PFAS Patients Act of 2026

This bill requires the Agency for Toxic Substances and Disease Registry (ATSDR) to partner with the National Academies to assess the health effects of per- and polyfluoroalkyl substances (PFAS) found in human tissues and develop clinical recommendations for addressing them. It mandates that this assessment be completed within 2 years of the law's enactment, updated every 5 years, and includes input from PFAS-exposed communities. Based on these assessments, ATSDR must issue and regularly update public clinical guidance for healthcare providers and public health authorities on managing PFAS health effects. The guidance must be posted online and shared with state/local health officials and medical professionals within 5 years of the agreement and every 5 years thereafter.